Rivia raises $15M to fix the broken data infrastructure behind clinical trials

Rivia, a Zurich-based company specializing in clinical trial intelligence, has secured $15 million in Series A funding to address critical data infrastructure challenges in drug development. This investment, led by Earlybird and supported by Defiant and existing investors, will bolster Rivia's mission to create a more efficient and intelligent data layer for clinical trials, a sector facing increasing regulatory scrutiny and financial pressures. The company's innovative data engine aims to standardize and streamline the complex process of integrating and analyzing data from thousands of disparate sources. The core of Rivia's solution is its proprietary data engine, designed to ingest and harmonize heterogeneous data files in real time. This engine applies trial-specific scientific logic through a library of reusable configurations, feeding clean, integrated data directly into operational workflows. This foundation now supports a new suite of embedded AI agents, starting with Spark, which converts natural language into publication-grade clinical visualizations. Future agents will focus on proactive data quality monitoring, early deviation detection, and intelligent prioritization, enhancing the overall integrity and efficiency of clinical trials. This funding arrives at a pivotal moment for the pharmaceutical industry, where shrinking margins and tightening regulatory demands necessitate more sophisticated data management. Traditional clinical trial infrastructure, often relying on fragmented systems and manual data stitching, lags behind the exponential growth in data volume and complexity from sources like wearables and specialty labs. Rivia's approach, by building a robust data engine before layering AI, aims to provide the essential scaffolding for accurate interpretation and faster, more proactive decision-making in drug development, ultimately supporting European efforts to build more resilient digital health ecosystems.